OBI-999 by OBI Pharma for Breast Cancer: Likelihood of Approval
OBI-999 is under clinical development by OBI Pharma and currently in Phase II for Breast Cancer.
T Ai Pei Hong Kong Globaldata Pharmaceutical Intelligence Center Breast Cancer Phase Transition Success Rate Model Globoh Specific
Source: pharmaceutical-technology.com